Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Gross Profit: 2015-2024

Historic Gross Profit for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $57.9 million.

  • Intellia Therapeutics' Gross Profit rose 51.27% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year increase of 33.52%. This contributed to the annual value of $57.9 million for FY2024, which is 59.55% up from last year.
  • Intellia Therapeutics' Gross Profit amounted to $57.9 million in FY2024, which was up 59.55% from $36.3 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Gross Profit high stood at $58.0 million for FY2020, and its period low was $33.1 million during FY2021.
  • Its 3-year average for Gross Profit is $48.8 million, with a median of $52.1 million in 2022.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 43.01% in 2021, then soared by 59.55% in 2024.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Gross Profit stood at $58.0 million in 2020, then slumped by 43.01% to $33.1 million in 2021, then spiked by 57.69% to $52.1 million in 2022, then tumbled by 30.40% to $36.3 million in 2023, then skyrocketed by 59.55% to $57.9 million in 2024.